Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

First patient in current dose cohort exhibited no progression of her cancer three months aftertreatm

 The study is being conducted at Moffitt Cancer Center ("Moffitt"). The Phase 1 study is eva

Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limitin

Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) Director Arnold Baskies purchased 5,000 share

Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) CEO Amit Kumar acquired 7,000 shares of Anixa

HC Wainwright & Co. analyst Yi Chen maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in A

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Austr

SAN JOSE, Calif., Sept. 16, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company")

Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analys

SAN JOSE, Calif., Sept. 9, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (

Presentation to highlight Anixa's clinical progress and collaborations with leading cancer research

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Breast cancer vaccine final Phase 1 data shows all primary endpoints were met and protocol-defined i

Ovarian cancer CAR-T therapy, lira-cel, advances to highest dose level to date in fifth cohort with

Anixa Biosciences (ANIX) might move higher on growing optimism about its earnings prospects, which i

HTLD, YEXT, ANIX, WVE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on July 22, 20

Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c

Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform C

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology c

Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limitin

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Breast cancer vaccine presentation includes final Phase 1 data showing all major primary endpoints w

Anixa advances cancer vaccines and CAR-T therapies, supported by positive early data, a planned phas

Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations fro

Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analys

Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven

Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the preven

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Multiple patients have survived substantially beyond expected median survival, including onepatient

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology co

Lira-cel continues to exhibit positive survival data in ongoing Phase 1 clinical trialSAN JOSE, Cali

Phase 1 study met primary endpoints, showed safety and tolerability at the maximum tolerated dose, a

Dr. Robert Wenham of Moffitt Cancer Center and principal investigator of the trial to present lira-c

Notice of Allowance marks first Korean patent covering Anixa's breast cancer vaccine platformExp

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, R

  On Tuesday, 647 companies set new 52-week lows.

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

  During Tuesday's session, 454 stocks hit new 52-week lows.

    Before 10 a.m. ET on Friday, 571 companies hit new 52-week highs.

Gainers

Gainers Immutep Limited (NASDAQ: IMMP) shares jumped 198.6% to $6.42 after the company said its C

Gainers Extraction Oil & Gas, Inc. (NASDAQ: XOG) shares climbed 247.9% to close at $1.48 on M